Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | GRM5 | P41594 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644705 | 0.84 | ALDH1A1 (0.38) | HSD17B10MEN1KMT2AHPGDKDM4E | |
| SCHEMBL22242112 | 0.78 | CYP1A2 (0.51) | NPSR1HSD17B10RAB9ANPC1L3MBTL1 | |
| SCHEMBL4035843 | 0.78 | CYP2C19 (0.50) | RAB9ANPC1L3MBTL1HPGDPOLB | |
| SCHEMBL24347521 | 0.75 | NPSR1 (0.49) | NPSR1HSD17B10RAB9ANPC1L3MBTL1 | |
| SCHEMBL30597170 | 0.75 | MEN1 (0.38) | HSD17B10RAB9ANPC1MEN1KMT2A | |
| SCHEMBL4647621 | 0.74 | CYP1A2 (0.38) | HSD17B10ALDH1A1 | |
| SCHEMBL6027180 | 0.74 | P2RX7 (0.51) | RAB9ANPC1L3MBTL1GRM5HPGD | |
| SCHEMBL2599179 | 0.73 | MAPT (0.44) | L3MBTL1ALDH1A1 | |
| SCHEMBL1647703 | 0.72 | HSD11B1 (0.37) | KMT2ALMNAKDM4EALDH1A1 | |
| SCHEMBL15441133 | 0.72 | CA12 (0.50) | HSD17B10MEN1KMT2AHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1897944-A | Benzenesulfonamido-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD-1) for the treatment of diabetes and obesity | AGOURON PHARMA (US) | 2007-01-17 | — | — | CN | disclosed |
| EP-1696915-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | Pfizer, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005060963-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | PFIZER INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AGOURON PHARMACEUTICALS, INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B11, HSD11B2 | NPSR1 1936/4885HSD17B10 22/4885RAB9A 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.